Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 25, 2010 Brian Orelli	No Way to Hide This Drug Approval FDA trumps Acorda on its good news. The biotech announced Food and Drug Administration approval of Ampyra, its drug to help multiple sclerosis patients walk better after the markets closed on Friday.
The Motley Fool June 3, 2008 Brian Orelli	Taking a Walk With a 10-Bagger Acorda Therapeutics gets it done with phase 3 trial data on a new MS drug.
BusinessWeek April 9, 2007 Gene G. Marcial	Acorda Tackles Multiple Sclerosis A Corda Therapeutics isn't your typical biotech.
The Motley Fool September 25, 2007 Brian Lawler	Acorda at a Glance Acorda Therapeutics has given astute biotech investors quite a ride over the last 12 months following positive results for their lead drug, Fampridine-SR. That drug now takes another step towards FDA approval. Investors, take note.
The Motley Fool October 15, 2009 Robert Steyer	Little Discord on Acorda Drug FDA advisory panel overwhelmingly backs a drug to improve the walking ability of multiple sclerosis patients.
The Motley Fool October 7, 2009 Robert Steyer	Acorda's Upcoming Excitement Acorda is seeking FDA approval for a pill to improve the walking ability of multiple sclerosis patients.
The Motley Fool December 11, 2006 Brian Lawler	Acorda Calls for 2 More Trials It'll be awhile before the FDA makes its decision on the pharma's new MS drug and the stock price settles down.
The Motley Fool September 26, 2006 Brian Lawler	Four-Bagger Biotech in One Day Acorda's shares zoomed up, but potential investors should be cautious.
The Motley Fool December 5, 2007 Brian Orelli	Early Bird Gets the MS Worm Teva's multiple sclerosis drug COPAXONE performs well in a label-expanding trial.
The Motley Fool September 22, 2010 Jordan DiPietro	A Huge Victory for Novartis MS oral drug is approved.
The Motley Fool January 29, 2008 Brian Lawler	Acorda Rides the Wave Acorda Therapeutics announces positive clinical trial data on its lead multiple sclerosis drug.
The Motley Fool November 3, 2006 Brian Lawler	Acorda's Wild Ride Positive trials help propel the stock to seven times its yearly low. Investors in the pharmaceutical since the company's IPO have been richly rewarded for their patience this year.
Chemistry World April 2, 2007	European Generics Suppliers Hit Generics drug manufacturers have lost a slice of their market with the reinstatement of a European patent covering Merck's multi-billion-dollar osteoporosis drug, Fosamax.
Bio-IT World November 2005 Patrick R. Scanlon	Patent Term Extension Primer U.S. patent law includes provisions for extending the patent term of medical devices and pharmaceuticals in instances when lengthy FDA approval is taking place during the term.
The Motley Fool December 7, 2004 Charly Travers	Spin the Medicine Bottle Is a new MS drug going to be a top seller or a bottom-dweller? Here's how to find out. Before investing in any pharmaceutical company with a product in development, go through this exercise to estimate the new drug's potential.
InternetNews December 21, 2009	Microsoft to Mirror Your Real Condition Online If a patent that Microsoft is seeking is granted, the old saw that "on the Internet nobody knows you're a dog" may be history.
The Motley Fool October 27, 2009 Brian Orelli	Small Market, Small Acquisition, Still a Good Move BioMarin does everything small.
The Motley Fool March 15, 2007 Brian Lawler	Dueling Fools: Elan Bear Rebuttal With so many risks and unknowns embedded in Tysabri, investors should not be convinced Elan can provide a miracle.
The Motley Fool July 2, 2009 Brian Orelli	Deal Struck, Shares Stuck Acorda Therapeutics secured a decent upfront payment to license the ex-U.S. rights to its multiple sclerosis drug, Fampridine-SR, from the perfect partner. Unfortunately, investors still smacked the stock down nearly 15% yesterday.
The Motley Fool September 14, 2006 Brian Lawler	Close Failure for Genzyme Will Genzyme's Campath get approval? Investors shouldn't hold their breath.
The Motley Fool March 13, 2008 Stephen Albainy-Jenei	Pfizer's Celebrex Aches and Pains The Court of Appeals for the Federal Circuit upholds a lower court's ruling that found Teva Pharmaceutical had infringed two of Pfizer's patents for Celebrex.
The Motley Fool August 29, 2006 Brian Lawler	More Good News for Rituxan Genentech and Biogen Idec's drug shows positive results against multiple sclerosis. Investors, take note.
The Motley Fool March 31, 2010 Brian Orelli	When One Patent Means So Much The loss of patents on genes could have far-reaching consequences for drug companies.
The Motley Fool July 26, 2007 Brian Orelli	Barr Gets Sued, Again This is starting to be a bad habit at Barr Pharmaceutical. The drug maker has just been sued for the third time in as many weeks. The latest one is by Schering-Plough, over patent infringement of its brain cancer treatment drug.
The Motley Fool September 12, 2005 M.D. Mitchell	Big Problems for Big Pharma Creating new drugs is never easy, but the companies that excel in three key areas are the ones for investors to watch.
The Motley Fool May 26, 2010 Brian Orelli	Blockbuster Drugs Aimed at Busting MS Multiple sclerosis is a large market with more entrants coming.
InternetNews June 1, 2007 Stuart J. Johnston	MS Wins Right to Challenge Patent's Ownership Eolas Technologies may not be due $521 million after all in IE patent dispute.
Wall Street & Technology September 19, 2006 Paul Allen	Patent Processing For both the patent holders and potential transgressors, technology patents can be a high-stakes game in the financial world, in both monetary awards and ongoing business feasibility.
The Motley Fool March 3, 2011 Brian Orelli	3 Cheers for an FDA Rejection German drugmaker Merck said that the Food and Drug Administration had turned down its multiple sclerosis drug cladribine. The pill would have competed with Novartis' Gilenya, which gained FDA approval last year.
The Motley Fool April 29, 2011 Brian Orelli	Oral Multiple Sclerosis Drugs Heat Up Watch out Novartis and Gilenya.
InternetNews August 19, 2004 Ryan Naraine	USPTO Close to Rejecting Plug-in Patent The U.S patent office is a step closer to overturning the controversial browser plug-in patent at the heart of a dispute between Microsoft and Eolas Technologies.
InternetNews December 14, 2006 Nicholas Carlson	Google's Search For Patents Google Patent Search is a natural extension of its mission to make public domain government information more easily accessible.
The Motley Fool May 8, 2007 Mike Havrilla	Is VISICU on the Verge? There are some positive developments regarding a key patent. Investors who have been monitoring VISICU since it reported positive results last quarter may want to take a second look at the company now.
Pharmaceutical Executive June 1, 2005 Peter J. Pitts	Opinion: Uncle Sam, MD Is having the government pursue a patent the best way of placing important discoveries in the public domain? It depends. Is putting the government in control of drug development in the best interests of public health? No.
Information Today June 14, 2010 George H. Pike	U.S. Patent Office and Google to Provide Free Bulk Patent and Trademark Data On June 2, 2010, the United States Patent and Trademark Office announced an agreement to make more than 10 terabytes of bulk electronic patent and trademark data available through Google.
InternetNews November 16, 2005 Susan Kuchinskas	PubPat Claims 'Prior Art' on JPEG Patent The Public Patent Foundation is asking the U.S. Patent office to take another look at the data compression format.
InternetNews May 12, 2010	USPTO Upholds i4i XML Patent in Microsoft Fight Microsoft has been dealt another setback in its long-running dispute with i4i as the U.S. Patent and Trademark Office has determined that the Toronto firm's Custom XML patent is valid.
The Motley Fool February 10, 2010 Brian Orelli	Icahn's Smiling -- Should We Be? Biogen Idec's fourth quarter results must have made Carl Icahn smile. But the guidance for next year gives pause.
The Motley Fool August 13, 2010 Brian Orelli	Already a Slippery Slope for Eli Lilly The company gets a whiff of what its patent cliff might be like.
InternetNews September 28, 2005 Susan Kuchinskas	Eolas Patent Survives Re-Exam The U.S. Patent & Trademark Office seems inclined to let an early patent covering browser applets stand, despite opposition from Microsoft and a band of Internet gurus.
Entrepreneur May 2003 Joshua Kurlantzick	Losing the Race Is the Patent Office's slowness putting U.S. innovation at risk?
InternetNews January 8, 2010	New Hints on Apple Plans in Patent Filings Touchscreen technology could be proliferating to more Mac devices, if the filings are any indication.
Information Today December 10, 2013	EBSCO Discovery Service Integrates Full-Text Patents EBSCO Information Services added content from the United States Patent and Trademark Office to EBSCO Discovery Service.
IEEE Spectrum October 2007 Gunderman & Hammond	How the U.S. Patent Office's New Patent Rules Affect You What you need to know about the USPTO's new patent rules to protect your intellectual property.
The Motley Fool August 10, 2010 Brian Orelli	Elan's Alternative to Strategic Alternatives Sometimes doing nothing is the best option.
The Motley Fool November 15, 2007 Charly Travers	John Edwards, Frozen Caveman Lawyer Presidential hopeful John Edwards' health-care plans could destroy drug research and development in this country by removing the patent protection on breakthrough drugs.
InternetNews February 12, 2004 Alexander Wolfe	Microsoft Locks Up XML Patent The software giant lands another XML patent, which will bolster its product development scheme.
AskMen.com March 19, 2003 Steve Richer	How To: Patent An Invention Investors will not do business with you until you have that precious little number that guarantees that you own the rights to the invention. Read on to see how you can obtain a patent.
InternetNews September 27, 2006 Michael Hickins	IBM Pushes New Patent Policies Patent reform may be on the way, but IBM has decided to change the system on its own and is leading by example.
Financial Advisor October 2006 Michael Brier	Patently Foolish? Allowing financial firms to patent tax strategies may mean you and your clients have to foot the bill.